Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2020

June 2020 | 131 pages | ID: HDF84309EB4EN
Global Markets Direct

Abstracts

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema - Pipeline Review, H1 2020, provides an overview of the Hereditary Angioedema (Immunology) pipeline landscape.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hereditary Angioedema (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 1, 5, 4, 10 and 2 respectively.
Hereditary Angioedema (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (Immunology).
• The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hereditary Angioedema (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hereditary Angioedema (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Attune Pharmaceuticals, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioMarin Pharmaceutical Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Generium, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Intellia Therapeutics Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Octapharma AG, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharvaris BV, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by RegenxBio Inc, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Serpinx BV, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H1 2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Adverum Biotechnologies Inc
Attune Pharmaceuticals
BioCryst Pharmaceuticals Inc
BioMarin Pharmaceutical Inc
CSL Ltd
Generium
iBio Inc
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Octapharma AG
Pharming Group NV
Pharvaris BV
RegenxBio Inc
Serpinx BV
Takeda Pharmaceutical Co Ltd
Verseon Corp